Compare · LMRI vs NTRA
LMRI vs NTRA
Side-by-side comparison of Lumexa Imaging Holdings Inc. (LMRI) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LMRI and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $58.35B, about 56.3x LMRI ($1.04B).
- NTRA has been more active in the news (12 items in the past 4 weeks vs 2 for LMRI).
- NTRA has more recent analyst coverage (25 ratings vs 11 for LMRI).
- Company
- Lumexa Imaging Holdings Inc.
- Natera Inc.
- Price
- -
- -
- Market cap
- $1.04B
- $58.35B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2015
- News (4w)
- 2
- 12
- Recent ratings
- 11
- 25
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest LMRI
- Truist initiated coverage on Lumexa Imaging Holdings with a new price target
- KeyBanc Capital Markets initiated coverage on Lumexa Imaging Holdings with a new price target
- Lumexa Imaging Announces Participation in Upcoming Investor Conferences
- SEC Form SCHEDULE 13G filed by Lumexa Imaging Holdings Inc.
- SEC Form 10-Q filed by Lumexa Imaging Holdings Inc.
- Lumexa Imaging Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Lumexa Imaging Announces Second Quarter 2026 Results
- Lumexa Imaging Announces Second Quarter 2026 Earnings Conference Call Date
- Lumexa Imaging Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Director Mittl Robert Louis Jr. was granted 19,358 shares (SEC Form 4)
Latest NTRA
- SEC Form 4 filed by Natera Inc.
- Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
- Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
- SEC Form 4 filed by Natera Inc.
- FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
- Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
- New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
- Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $1,242,645 worth of shares (3,000 units at $414.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 106,914 units (SEC Form 4)
- CEO AND PRESIDENT Chapman Steven Leonard sold $526,144 worth of shares (1,273 units at $413.31) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 96,926 units (SEC Form 4)